The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also interacting with medicine developers and making use of real-world data to monitor the safety and effectiveness of medicines use ... d in patients with COVID-19. more

An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages 18 Febr. 2021

11 March 2021

7 April 2021

Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte ... d with the Ebola virus: BCX4430 (Biocryst); Brincidofovir (Chimerix); Favipiravir (Fujifilm Corporation/Toyama); TKM-100802 (Tekmira); AVI-7537 (Sarepta); ZMapp (Leafbio Inc.); Anti-Ebola F(ab’)2 (Fab’entech). The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases. more